These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9783412)

  • 1. [The prospects for improving chemical cholera vaccines].
    Markov EIu; Maramovich AS; Golubinskiĭ EP; Urbanovich LIa
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):91-6. PubMed ID: 9783412
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholera vaccines.
    Ryan ET; Calderwood SB
    Clin Infect Dis; 2000 Aug; 31(2):561-5. PubMed ID: 10987721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccination against cholera: what prospects?].
    Pierre P; Lucas G; Vaerman JP
    Ann Soc Belg Med Trop; 1988 Jun; 68(2):83-93. PubMed ID: 3071278
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunisation against cholera with a Ty21a-cholera hybrid.
    La Brooy JT; Forrest B; Bartholomeusz C
    Ann Sclavo Collana Monogr; 1986; 3(1-2):143-7. PubMed ID: 3426872
    [No Abstract]   [Full Text] [Related]  

  • 5. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial Commentary: Resurrecting a Live Oral Cholera Vaccine.
    Harris JB
    Clin Infect Dis; 2016 Jun; 62(11):1336-7. PubMed ID: 27001802
    [No Abstract]   [Full Text] [Related]  

  • 7. Live oral vaccines against cholera: an update.
    Levine MM; Kaper JB
    Vaccine; 1993; 11(2):207-12. PubMed ID: 8438619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR.
    Albert MJ; Alam K; Ansaruzzaman M; Qadri F; Sack RB
    J Infect Dis; 1994 Jan; 169(1):230-1. PubMed ID: 8277193
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ; Fürer E; Germanier R
    Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmid-induced loss of virulence in Vibrio cholerae.
    Sinha VB; Srivastava BS
    Nature; 1978 Dec; 276(5689):708-9. PubMed ID: 732874
    [No Abstract]   [Full Text] [Related]  

  • 11. Obtaining and Characteristic of Antibodies to Vibrio cholerae Protective Antigens Conjugated with Gold Nanoparticles.
    Dykman LA; Volokh OA; Gromova OV; Durakova OS; Vorobeva SA; Kireev MN; Livanova LF; Nikiforov AK; Shchyogolev SY; Kutyrev VV
    Dokl Biochem Biophys; 2020 Jan; 490(1):19-21. PubMed ID: 32342306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
    Viret JF; Dietrich G; Favre D
    Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with registered mucosal vaccines.
    Dietrich G; Griot-Wenk M; Metcalfe IC; Lang AB; Viret JF
    Vaccine; 2003 Jan; 21(7-8):678-83. PubMed ID: 12531339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638.
    Talavera A; Año G; García H; Moreira T; Delgado H; Riverón L; Gil S; Miranda A; Cedré B; Valmaseda T; Pino Y; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 May; 24(18):3746-9. PubMed ID: 16085342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholera: Immunity and Prospects in Vaccine Development.
    Harris JB
    J Infect Dis; 2018 Oct; 218(suppl_3):S141-S146. PubMed ID: 30184117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-O1 Vibrio cholerae and epidemic cholera.
    Commun Dis Rep CDR Wkly; 1993 Jun; 3(24):107. PubMed ID: 7693194
    [No Abstract]   [Full Text] [Related]  

  • 17. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.
    Levine MM; Kaper JB; Herrington D; Ketley J; Losonsky G; Tacket CO; Tall B; Cryz S
    Lancet; 1988 Aug; 2(8609):467-70. PubMed ID: 2900401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Present status of cholera vaccines.
    Levine MM; Black RE; Clements ML; Kaper JB
    Biochem Soc Trans; 1984 Apr; 12(2):200-2. PubMed ID: 6724113
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of oral cholera vaccines during pregnancy in developing countries.
    Khan AI; Islam MT; Qadri F
    Hum Vaccin Immunother; 2017 Oct; 13(10):2245-2246. PubMed ID: 28825876
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.